Peptide Antibiotics Gain Momentum Amid Rising Resistance and R&D Advances
Peptide antibiotics appeal is increased by their capacity to target germs that are resistant to many drugs, as well as by developments in peptide synthesis and drug delivery technology. Other growth factors include increasing pharmaceutical R&D expenditures, growing awareness of hospital-acquired infections, and encouraging government programs for the development of novel antibiotics.
Key Growth Drivers and Opportunities
Rising Antibiotic Resistance: The increasing antibiotics resistance makes the conventional antibiotics less effective against bacteria that are resistant to multiple drugs leading towards adoption of peptide antibiotics. Novel peptide-based solutions have higher investments from government, healthcare institutions, and pharmaceutical corporations in order to counter the increasing global health danger posed by superbugs and the pressing need for new, effective therapies. With increasing demand for potent antimicrobials, the peptide antibiotics industry is seeing a surge in research, development, and commercialization.
Challenges
The peptide antibiotics mostly requires complicated and complex synthesis processes that can be expensive, consumes more time and labor-intensive as they need creating accurate sequences of amino acids with certain structures and clear modifications. To improve stability or activity of some procedures, solid-phase peptide synthesis, purification procedures, and chemical alterations are needed with each call for specific tools and knowledge. This intricacy increases production costs and restricts scalability.
Innovation and Expansion
New peptide antibiotic stops bacteria by binding where no drug has before
In March 2025, the lariocidin was discovered which is a lasso peptide making a breakthrough step ahead in antibiotics. Found by McMaster University researchers binds to a bacterial ribosome location which was previously untargeted, preventing protein production and leading to incorrect coding.
The antibiotics peptide effectively counters the multi-drug-resistant bacteria in animal models and lab studies, having a minimum toxicity and lower potential for resistance development.
New Human-Derived Peptides Show Promise Against Superbugs in June 2025 Breakthrough
In June 2025, a novel class of antimicrobial peptides (AMPs) have been identified by Researchers at Universitat Autònoma de Barcelona that is embedded within human glycosaminoglycan-binding proteins. In both in vitro experiments and mice sepsis models, HBP-5 showed strong, targeted efficacy against multidrug-resistant Gram-negative bacteria with no harm to human cells.
The Lariocidin's therapeutic potential in hostile biological conditions is further enhanced by its extraordinary durability against enzymatic degradation due to its unique lasso structure.
First Peptide-Based Long-Lasting Frown Line Treatment
In September 2022, The U.S. FDA has cleared DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, according to a statement released by Revance Therapeutics. Since DAXXIFY is the first and only peptide-formulated neuromodulator that provides long-lasting cosmetic results, this is a significant milestone.
In comparison to current botulinum toxin treatments, the product is intended to lessen the appearance of frown lines and may have a longer duration of action.
Innovation in Antibiotics, Expand Markets
The key players operating in the peptide antibiotics market include, Merck & Co., Inc., Monarch Pharmachem, AbbVie Inc., VERRA, Melinta Therapeutics LLC, and others. Long-term goals consist of to improve product quality and scalability, peptide antibiotic firms are concentrating on innovation through robust research and development, strategic partnerships, and economical production.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
15 hours ago
- Gizmodo
Gluten Could Be Wrongly Blamed for Americans' Stomach Troubles
For many of us, gluten is a dietary villain, capable of causing all sorts of gastrointestinal troubles. Research out this week looks to complicate that narrative, however, finding that people are sometimes wrongly blaming gluten for triggering their symptoms of irritable bowel syndrome. Scientists at McMaster University in Canada conducted the study, a small, randomized trial of IBS patients. People became sicker just as often after eating food containing gluten or wheat as they did after eating food without the ingredient, they found. Gluten is likely safer to eat for those with IBS than commonly thought, the researchers say. 'These findings suggest that expectations played a major role in symptom generation and that only some of these patients could benefit from gluten or wheat restriction,' they wrote in their paper, published Monday in The Lancet Gastroenetrology and Hepatology. IBS is a complex, chronic, and relatively common condition, estimated to affect between 5 and 10% of the population worldwide (including up to 45 million people in the U.S.). Its symptoms include stomach pain, bloating, and diarrhea or constipation. Unlike the closely named inflammatory bowel disorder, IBS isn't marked by physical changes or visible damage along the digestive tract, but it can still be a debilitating burden for many, with around 20% of sufferers experiencing severe bouts. The exact causes of IBS remain unclear, though scientists have speculated it can arise from a miscommunication between the nerves found in the gut and the brain. People with IBS tend to report having specific triggers that can cause a flare-up of illness, gluten included, and often manage their condition by avoiding these triggers. The researchers behind the new study aimed to better understand gluten's potential role in IBS, so they recruited over two dozen people with IBS for their randomized, double-blinded trial, all of whom had reported improving after switching to a gluten-free diet. At first, the volunteers were randomly assigned to one of three groups. All the groups were first told to eat cereal bars for a week. One group ate bars made with flour containing gluten, the second ate bars made with wheat flour, and the third ate bars made with gluten- and wheat-free flour. Afterward, the volunteers took a break for two weeks. Then they switched to eating the bars they hadn't eaten yet for another round of testing, a process repeated twice. By the study's end, all the volunteers had eaten all three kinds of bars, though on different schedules and without knowing which bars they had eaten on a given week. A total of 28 people completed the trial. A significant percentage of people reported having worsening IBS symptoms after eating gluten or wheat bars, the study showed, but about just as often as they did after eating non-gluten/wheat bars (roughly a third experienced worsening IBS during each of the three conditions). 93% of participants also reported having adverse events after each scenario of bar-eating. Interestingly enough, tests of the participants' stool found that only a third strictly followed their diets as instructed, with likely many fearing they would get sick. The findings are based on a very small sample size, so it's not yet certain that they apply to the general population of people with IBS tied to gluten. There are also, of course, digestive conditions clearly caused by an intolerance to gluten, particularly celiac disease. And the researchers aren't saying gluten can't sometimes be a genuine trigger for people's IBS. But they argue that in many cases, people's negative perception of gluten is causing a nocebo effect, the dark cousin of the placebo effect. In other words, someone's belief that gluten is bad for them can potentially spark or worsen the IBS symptoms seen after eating it, rather than gluten itself. The researchers say better communication and follow-up care from doctors are needed for IBS patients, given the findings. 'What we need to improve in our clinical management of these patients is to work with them further, not just tell them that gluten is not the trigger and move on. Many of them may benefit from psychological support and guidance to help destigmatize gluten and wheat and reintroduce them safely in their diet,' said senior author Premysl Bercik, a professor at McMaster's Department of Medicine, in a statement from the university. That may be easier said than done, though. The researchers note that most patients, upon learning the team's findings, staunchly refused to entertain the idea of gluten not being a trigger for their IBS symptoms. So it looks like gluten may need a promotional campaign to win back its reputation.
Hamilton Spectator
a day ago
- Hamilton Spectator
Dark skin was part of his identity until a medical condition stole it away
There was no support for Shahnawaz Towheed when he developed an auto-immune condition that causes the skin to lose its pigment. 'I didn't know anyone else who had my condition, as it only affects about one per cent of the population,' Towheed said. 'There was this sense of feeling alone and not feeling understood either … You sort of hide yourself from certain situations in which people might notice your skin or call it out.' To combat the isolation, the 26-year-old McMaster University medical student created virtual support groups for vitiligo himself — first in the United Kingdom (U.K.) and now in Canada. Finding people who looked like him and who could relate to his story was just as important as medical care for the condition, Towheed said. 'That sense of hopelessness, fear, anxiety and just ultimately not really feeling content with the way you are and the way you look,' Towheed said. 'It took many years, but I was able to allow that to shape me into someone who now has aspirations to support others who are going through the same thing.' Filling that gap in services is so important that Towheed set out to prove the worth of support groups for vitiligo. He was the lead author on a study presented to the Annual Meeting of the British Association of Dermatologists on July 2 in Glasgow. 'I thought it was received in a way that people understood the need,' Towheed said. 'A lot of the presentations there tend to be focused more on medical considerations regarding vitiligo or just things that don't really focus on the emotional or the identity challenges that people can have.' Shahnawaz Towheed as a child before vitiligo took all of his skin pigment. Towheed was six years old when he started to lose dark brown pigment on his left thigh and was diagnosed with vitiligo . His family tried every treatment, but it didn't stop the steady progress of the condition that saw him lose all his pigment by the age of 12. 'I felt a sense of shame and identity loss,' Towheed said. 'Part of my identity was someone who is South Asian and has dark skin and that was something that was gradually taken away.' With nowhere to turn for emotional support in Canada, he eventually teamed up with the Vitiligo Society in the U.K., which supports people living with the condition. He set up a virtual support group in 2023, facilitated the sessions and got feedback from patients on how it was working for the study. 'It became a really good training ground for me to understand how I can apply some of the things that the U.K. group is doing to Canada,' Towheed said. 'A lot of that became the blueprint for what we are doing now.' McMaster University medical student Shahnawaz Towheed created support groups in Canada and the United States so people with vitiligo would not feel so isolated. Towheed co-founded Vitiligo Voices Canada last year to bring support closer to home. It can be found on Instagram at @VitiligoVoicesCanada and on Facebook. 'There's a lot of people out there who may not know about the service and can really benefit,' Towheed said. 'So just making sure that people know they're not alone.' As Towheed is about to enter his last year of medical school this fall, he's considering specializing in psycho dermatology. 'That's actually what my research is really focused on is that mind skin connection,' Towheed said. 'I feel like it's something that I can offer the most to given my connection to it.' Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Hamilton Spectator
2 days ago
- Hamilton Spectator
Canadian market to see generic Ozempic and Wegovy come January. What does that mean for Hamilton?
The nearing expiration date for the patent on Ozempic and Wegovy is making way for generic versions of the weight-loss and diabetic drugs to potentially flood the Canadian market. Denmark-based health-care company Novo Nordisk failed to pay a maintenance fee and lost the patent, which expires in January. Already, American telehealth company His and Hers Health said it will offer the generic medication in Canada. And, as of May 31, Health Canada had five applications under review from other companies wanting to sell generic versions of semaglutide drugs like Ozempic, which is used to treat adults with Type 2 diabetes, and Wegovy, which is used to treat obesity. Both health issues are prevalent locally, with a 2024 public health report showing the city's average body mass index was higher than Ontario's average and about 13 per cent of residents 20 and older lived with diabetes in 2020. Deaths due to diabetes were about three times higher for Hamilton residents living in low-income areas. So what does this mean for Hamilton? Dr. Hertzel Gerstein, a diabetes specialist, researcher and McMaster University professor. Dr. Hertzel Gerstein, a diabetes specialist, researcher and McMaster University professor, spoke with The Spectator about what to expect with the introduction of generic semaglutide drugs. Semaglutide is a synthetic injectable drug that mimics the naturally-occurring hormone GLP-1, released when eating. The hormone tells the body when it is full and controls when the stomach is emptied. The drug also tells the pancreas to release insulin, reducing blood sugar levels. Semaglutide leads to an average of five to 10 per cent weight loss over several months. This means someone weighing 200 pounds could lose 10 to 20 pounds. Usual recipients are middle-aged to older people, said Gerstein, but there is no minimum age that can receive a prescription. If Health Canada approves the drug, there should be little to no difference, said Gerstein. 'They need to show that it's the same, at least chemically, and that it is tolerated the same way,' he said. Again, if the drug is the same chemically, Gerstein said side effects should not differ drastically. The Health Canada approval process requires proof the drug is similar to the branded drug, including similar side effects. This includes reduced appetite, feeling full earlier than typical, constipation and nausea. Some have noticed less cravings, such as for pizza, pasta and even alcohol, said Gerstein. It is hard to predict how the generic drugs will impact population health, said Gerstein, but semaglutide is an 'extremely effective and beneficial drug' that has been tested extensively. The tests show the drug helps to control diabetes, reduce weight and lower long-term risks for heart attacks, strokes and other diseases. He expects the generic versions to be no different. The introduction of generic semaglutide would only have a significant impact on health issues in Hamilton if a lot of people started taking the drug as a result. Even with generic drugs available, he said that is not expected. While the new drugs will be cheaper, the provincial government and some private plans do not cover semaglutide used to treat obesity, said Gerstein. The best way to solve local health issues is to address root causes, he said, including city walkability and access to affordable, healthy foods. If both the doctor and patient are being honest, semaglutide should only be prescribed for legitimate medical reasons, said Gerstein. He said that is the only way patients can be reimbursed for their prescription. For people paying out-of-pocket, it is hard to know who is getting the drug and for what, he said. Drugs used to treat obesity, such as Wegovy, are prescribed on a case-by-case basis, which involves evaluating individual patients' lifestyles and health risks, he said. 'You don't treat the disease, you treat the patient,' said Gerstein. The prescribed diabetes drug is covered by the Ontario Drug Benefit Program, said Gerstein, while semaglutide for obesity is not. Costs for semaglutide drugs vary by dose, but can cost up to $500 per month . Prices for generic semaglutide could be 15 to 75 per cent of brand name drugs, said Dominic Tan, the deputy CEO of the pan-Canadian Pharmaceutical Alliance, which connects federal, provincial and territorial governments to negotiate drug prices and initiatives. The lower cost for consumers is a result of the company not having to pay to research and develop a new drug. Competition between generic drug companies can also drive the price down. Cheyenne Bholla is a reporter at The Hamilton Spectator. cbholla@ Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
